Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (CTC Detection and Enrichment Method, CTC Direct Detection Method, and CTC Analysis), Application (Clinical/Liqui

Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (CTC Detection and Enrichment Method, CTC Direct Detection Method, and CTC Analysis), Application (Clinical/Liquid Biopsy, and Research), and End-User (Hospitals and Clinics, Research and Academic Institutes, and Diagnostic Centers)

The Middle East & Africa circulating tumor cell (CTC) diagnostics market is expected to reach US$ 131.3 million by 2028 from US$ 75.3 million in 2021; it is estimated to grow at a CAGR of 8.3% during 2021-2028.

A circulating tumor cell is shed into the vasculature from the primary tumor and is carried around the body with the help of blood circulation. These circulating tumor cells are an indication of metastatic disease, and their detection can help in diagnosing the disease in its early stages and designing an appropriate treatment regime for the patient. In recent years, there have been significant advancements in isolation methods of circulating tumor cells for diagnosis. Immunoaffinity, physical properties, and direct analysis are among a few of the approaches used for circulating tumor cell isolation. Immunoaffinity is the affinity reactions that capture antibodies and target antigens present on cells of interest using magnetic beads, microfluidic flow, nanostructured substrate, microtubes, and leucocyte depletion. The microtube approach uses the biomimetic approach to stimulate the procedure of selectin-mediated cell adhesion for capturing CTCs. Even at a high flow rate of 4.8 ml/h, selectin-coated microtubes induce cell attachment and rolling, which promotes CTC binding with anti-Ep CAM (i.e., epithelial cell adhesion molecule) and anti-PSMA antibodies. The device had a capture efficiency of 50% and an average purity of 66%, and it detected circulating tumor cells in 14 of 14 patient blood samples examined, compared to 9 of 14 detected by the Cell Search system. Physical properties are also used to isolate circulating tumor cells from peripheral blood cells. A few of the common physical properties used for the isolation of CTCs are density gradient centrifugation, microfiltration, microfluidics, and dielectrophoresis. Thus, the ongoing developments and advancements in various isolation techniques for circulating tumor cells are expected to gain traction in the coming years.

During the COVID19 pandemic, healthcare providers had to reduce the number of diagnostic services and screening programs to redirect their efforts on the management of this disease. As a result, cancer patients became more susceptible to serious infections and faced issues such as interrupted cancer or standard medical care. Increased pressure from elevated hospitalization rates for COVID-19 patients led to the reprofiling of many hospitals and departments, including oncology clinics, to treat COVID-19 patients. These factors harmed the progress of the Middle East and Africa circulating tumor cell (CTC) diagnostics market.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the circulating tumor cell (CTC) diagnostics market. The Middle East & Africa circulating tumor cell (CTC) diagnostics market is expected to grow at a good CAGR during the forecast period.

Middle East & Africa Circulating Tumor Cell (CTC) Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Circulating Tumor Cell (CTC) Diagnostics Market Segmentation

By Technology

CTC detection and Enrichment Method CTC Direct Detection Methods CTC Analysis

By Application

Clinical/Liquid Biopsy Risk Assessment Screening and Monitoring Research Cancer Stem Cell and Tumorigenesis Research Drug/Therapy Development By End-User

Hospitals and Clinics Research and Academic Institutes Diagnostic Centers By Country

UAE Saudi Arabia South Africa Rest of Middle East & Africa Companies Mentioned

Thermo Fisher Scientific Inc. Stemcell Technologies Inc. Qiagen Advanced Cell Diagnostics, Inc. (Bio-Techne Corporation) Fluxion Biosciences

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa circulating tumor cell (CTC) diagnostics market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa circulating tumor cell (CTC) diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.